Ferrara JL, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am. 2010;30(1):75–101.

Article  PubMed  PubMed Central  Google Scholar 

Malard F, et al. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023;9(1):27.

Article  PubMed  Google Scholar 

Firoz BF, et al. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol. 2006;142(2):175–82.

Article  PubMed  Google Scholar 

Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66(4):515 .e1-18; quiz 533-4.

Article  PubMed Central  Google Scholar 

Vaidya T, et al. Inpatient management of mucocutaneous GVHD. Curr Dermatol Rep. 2019;8(4):258–78.

Article  PubMed  PubMed Central  Google Scholar 

Harris AC, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22(1):4–10.

Article  Google Scholar 

Holtan SG, et al. Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: a multicenter, retrospective study. Bone Marrow Transplantation v. 2022;57(9):1399–404.

Article  CAS  Google Scholar 

Naik H, et al. A pilot study comparing histological and immunophenotypic patterns in stage 4 skin graft vs host disease from toxic epidermal necrolysis. J Cutan Pathol. 2017;44(10):857–60.

Article  PubMed  Google Scholar 

Ullmann AJ, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.

Article  CAS  PubMed  Google Scholar 

Maertens J, et al. ECIL guidelines for preventing Pneumocystis Jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397–404.

Article  CAS  PubMed  Google Scholar 

Klein A, Miller KB, Sprague K, DesJardin JA, Snydman DR. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transpl. 2011;46:294–9.

Article  CAS  Google Scholar 

Wolfe D, et al. Letermovir prophylaxis and cytomegalovirus reactivation in adult hematopoietic cell transplant recipients with and without acute graft versus host disease. Cancers. 2021. https://doi.org/10.3390/cancers13215572.

Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the red man. Clin Dermatol. 2005;23(2):206–17.

Article  PubMed  Google Scholar 

Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016;42(1):15–31.

Article  PubMed  PubMed Central  Google Scholar 

Mielcarek M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Messina C, et al. Prevention and treatment of acute GvHD. Bone Marrow Transpl. 2008;41(Suppl 2):S65-70.

Article  CAS  Google Scholar 

Van Lint MT, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation. Blood. 1998;92(7):2288–93.

PubMed  Google Scholar 

Wang Y, et al. Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. BMC Med. 2024;22(1):176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine JE, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111(4):2470–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan S, et al. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis. Front Immunol. 2022;13: 954268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeiser R, et al. Ruxolitinib for glucocorticoid-refractory Acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–10.

Article  PubMed  Google Scholar 

Zhang MY, et al. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: systematic review and meta-analysis of randomised and non-randomised studies. PLoS ONE. 2022;17(7):e0271979.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Penack O, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 2024;11(2):e147-59.

Article  CAS  PubMed  Google Scholar 

Jagasia M, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abu-Dalle I, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transpl. 2014;20(11):1677–86.

Article  Google Scholar 

Mehta RS, et al. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transpl. 2021;56(6):1316–24.

Article  CAS  Google Scholar 

Weitz M, et al. Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database Syst Rev. 2014;2:Cd009759.

Google Scholar 

Solh MM, et al. Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD). Bone Marrow Transpl. 2023;58(2):168–74.

Article  CAS  Google Scholar 

Zhang H, et al. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence. 2015;9:105–11.

PubMed  PubMed Central  Google Scholar 

Thevenet U, et al. Infectious risks in patients treated with extracorporeal photopheresis for graft-versus-host disease: a retrospective cohort study. J Clin Apheresis. 2022;37(1):106–16.

Article  PubMed  Google Scholar 

Velickovic VM, et al. Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review. Ther Adv Hematol. 2020;11:2040620720977039.

Article  PubMed  PubMed Central  Google Scholar 

Kobbe G, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transpl. 2001;28(1):47–9.

Article  CAS  Google Scholar 

Couriel DR, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15(12):1555–62.

Article  CAS  Google Scholar 

Alousi AM, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the blood and marrow transplant clinical trials network. Blood. 2009;114(3):511–7.

Article  CAS  PubMed